Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Ruxolitinib plus carfilzomib & dexamethasone for patients with carfilzomib-refractory myeloma

Shebli Atrash, MD, Levine Cancer Institute, Charlotte, NC, shares some insights into the CARJAK trial (NCT03773107), which evaluated the safety and efficacy of ruxolitinib in combination with carfilzomib and dexamethasone in patients with carfilzomib-refractory multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.